

Rheumatoid Arthritis Drugs Market Size to Reach \$62.93 Billion, Growing at a CAGR 2.8% by 2027

Rise in the prevalence of rheumatoid arthritis, surge in geriatric population, and transition from symptom management to slowing the progression of the disease

PORTLAND, OR, UNITED STATES, September 16, 2021 /EINPresswire.com/ -- Rheumatoid arthritis is a disease that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly susceptible to develop this disease. The symptoms of rheumatoid arthritis include pain, stiffness, tender, and swelling of joints. Currently, no cure is available for rheumatoid arthritis.

[Rheumatoid Arthritis Drugs Market](#) was estimated at \$57.92 billion in 2019 and is expected to hit \$62.93 billion by 2027, registering a CAGR of 2.8% from 2020 to 2027. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends.

Request for Sample Report for More Insights@ <https://www.alliedmarketresearch.com/request-sample/3753>

Rise in the prevalence of rheumatoid arthritis, surge in geriatric population, and transition from symptom management to slowing the progression of the disease are the major factors that drive the growth of the global rheumatoid arthritis drugs market. On the other hand, side effects associated with the medication and higher cost of biologics & biosimilars restrain the market growth to some extent. Nevertheless, developments in the field of biosimilars and novel biologics are expected to pave the way for new opportunities in the industry.

Covid-19 scenario-

- The manufacturing of drugs are considered under essential services and thus, the global rheumatoid arthritis drugs market has not been much affected.

- Drugs used for treatment of rheumatoid arthritis like tocilizumab and hydroxychloroquine have also been studied for treatment of the novel corona virus.

The global rheumatoid arthritis drugs market is analyzed across drug class, administration, sales

channel, and region. Based on drug class, the disease-modifying anti-rheumatic drugs segment contributed to nearly four-fifths of the global rheumatoid arthritis drugs market share in 2019 and is projected to retain its dominance throughout the forecast period. The non-steroidal anti-inflammatory drugs segment, on the other hand, is expected to portray the highest CAGR of 3.5% from 2020 to 2027.

Based on route of administration, the parenteral segment accounted for nearly three-fourths of the global rheumatoid arthritis drugs market revenue in 2019 and is anticipated to rule the roost by 2027. Simultaneously, the oral segment would register the highest CAGR of 3.1% till 2027. Based on region, North America generated the highest in 2019, generating more than two-fourths of the global rheumatoid arthritis drugs market. At the same time, the Asia-Pacific region would showcase the fastest CAGR of 3.2% by 2027. The other two provinces studied in the report include Europe and LAMEA.

The key market players analyzed in the global rheumatoid arthritis drugs market report include Amgen Inc., UCB S.A., Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to brace their stand in the industry.

Inquiry for Buying@ <https://www.alliedmarketresearch.com/purchase-enquiry/3753>

Key Market Segments:

By Drug Class:-

- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Uric Acid Drugs
- Others

By Route of Administration:-

- Oral
- Parenteral

By Sales Channel:-

- Prescription-based Drugs
- Over-the-counter Drugs

By Region:-

- North America
- Europe
- Asia-Pacific

Trending Reports of Healthcare:

[Self-Monitoring Blood Glucose Strips Market](#) - Global Opportunity Analysis and Industry Forecast, 2019-2028

[Infection Prevention & Enteral Access Market](#) - Global Opportunity Analysis and Industry Forecast, 2019-2028

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 -503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/551568369>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

